Shenzhen Genocury Biotech Co., Ltd.

This is a very early study to check the safety and first signs of effectiveness of a new treatment called JY232 injection for people with multiple myeloma that has come back or stopped responding to other therapies. JY232 is a type of CAR-T cell therapy, where a patient's own imm…